The recovery of a kidney transplant recipient from COVID-19 has provided insight into the treatment of immunosuppressed coronavirus patients.
Implications of COVID-19 for inflammatory bowel disease patients with comments from Professor of Gastroenterology Dr. Giovanni Monteleone.
Clinical Trial Demonstrates Enhancement of Immune Response to HIV by Gilead’s TLR7 Agonist Vesatolimod
Gilead (Nasdaq: GILD) has announced clinical trial results demonstrating the enhancement of the immune response to HIV by the TLR7 agonist Vesatolimod.
Biocept, Inc. (Nasdaq: BIOC) has announced a clinical research publication further validating its cancer-detecting liquid biopsy platform.
Moderna, Inc. (Nasdaq: MRNA) has announced the completion of enrollment for a Phase 2 study evaluating its cytomegalovirus vaccine.
Research suggests that the coronavirus may remain infectious for up to 9 days on surfaces and may be deactivated by common disinfectants.
A novel immunotherapy approach combining natural killer cells with the cytokine IL-15 has led to a complete response of metastatic pancreatic cancer.
Three individuals in the state of Washington have tested presumptive-positive for the coronavirus according to a recent press release by the CDC.